The CYP2B6 C1459T SNP was examined among 426 participants of European ancestry in a pharmacogenetic placebo-controlled trial of bupropion for smoking cessation. Compared to smokers with the wild-type genotype, those with one or two T variants who received placebo reported higher levels of abstinence-induced cravings and were less likely to be abstinent at the end of treatment (Lerman et al., 2002). Bupropion treatment reversed the increased relapse risk among female carriers of the T variant. Indeed, among females with the variant, end-of-treatment abstinence rates were 15% on placebo versus 54% on bupropion (Lerman et al., 2002). In an independent bupropion placebo-controlled trial, the T variant at 1459 (one or two copies) moderated the effect of the ANKK1 Taq1A polymorphism on abstinence (David et al., 2007).
